Investing carries serious risks, including partial or total loss of capital. Please read the Key Investment Information Sheet and the Risk factors and login before investing.
Blue Armor 1A
What if vaccinating fish was the key to more profitable and sustainable aquaculture?
Aquaculture is the fastest-growing food production sector in the world, with over 52% of all fish consumed now coming from farming. Among these, Atlantic salmon farming dominates the market, reaching 3.8 million metric tons in 2020 and maintaining strong growth momentum with a compound annual growth rate (CAGR) of 6.5%.
This trend reflects the global demand for sustainable protein sources with a low carbon footprint, high profitability, and minimal use of arable land and freshwater.
However, this growth is constantly threatened by persistent health challenges. Viral infections continue to cause major financial losses—even in countries where vaccination is routinely used. At the same time, salmon lice infestations are the leading cause of indirect mortality in salmon farms, generating over €500 million in annual losses. No vaccine against salmon lice is currently available on the market.
A vaccine market highly concentrated and vulnerable
World Salmon Vaccine and drugs market is dominated by 3 players worldwide and represent a total of
Currently, the European salmon vaccine market is dominated by just two key players:
Pharmaq/Zoetis, offering three vaccines including one multivalent in Europe,
MSD Animal Health, offering a single vaccine.
This high level of concentration creates a near-monopoly, driving up costs, limiting product diversity, and increasing the risk of resistant variants emerging due to widespread use of the same vaccines. In addition, any supply chain disruption could lead to severe economic losses for producers.
Blue Armor’s innovation
Blue Armor is currently developing the first mRNA vaccine platform specifically designed for aquaculture, offering:
Flexibility: rapid adaptation to emerging strains and fast production in response to evolving demand,
Efficacy: strong immune responses with reduced doses per fish,
Safety: no harmful effects on fish, no toxic adjuvants, and no GMOs—making it safe for the environment.
Our pipeline includes vaccines targeting the major pathogens affecting salmon, along with a top-priority program to develop an innovative vaccine against salmon lice.
Blue Armor’s mRNA technology enables personalized, scalable, and safe solutions to address both viral and parasitic threats in modern aquaculture. Unlike conventional vaccines, our platform is not subject to GMO-related regulatory constraints and allows for a faster response to new variants—an essential advantage in a dynamic industry.
Initial focus on Norway: a high-impact entry market
Our initial commercial target is Norway, the world’s leading producer of Atlantic salmon. The Norwegian market alone represents approximately 300 million fish per year, making it an ideal environment to introduce and validate high-impact technologies in collaboration with local industry leaders.
After completing the initial phases of R&D, development, and regulatory registration, we anticipate a return on investment between year 6 and year 10, depending on the scenario (optimistic vs. conservative).
TAX SHELTER
45%
Investments in this company benefit from a 45% personal income tax reduction. Read more…
A remaining amount of €380,500 is available for the Tax Shelter benefit.
